Dihydrostreptomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dihydrostreptomycin
Accession Number
DB11512
Type
Small Molecule
Groups
Investigational, Vet approved
Description

Dihydrostreptomycin is an antibiotic.

Structure
Thumb
Synonyms
  • DHMS
  • DST
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  • N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
Product Ingredients
IngredientUNIICASInChI Key
Dihydrostreptomycin sulfateT7D4876IUE5490-27-7Not applicable
Categories
UNII
P2I6R8W6UA
CAS number
128-46-1
Weight
Average: 583.596
Monoisotopic: 583.281319788
Chemical Formula
C21H41N7O12
InChI Key
ASXBYYWOLISCLQ-HZYVHMACSA-N
InChI
InChI=1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
IUPAC Name
N-[(1R,2R,3S,4R,5R,6S)-3-carbamimidamido-4-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy}-2,5,6-trihydroxycyclohexyl]guanidine
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AceclofenacAceclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Dihydrostreptomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Dihydrostreptomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumDihydrostreptomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidDihydrostreptomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
AmpicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ApocyninApocynin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumDihydrostreptomycin may increase the respiratory depressant activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateDihydrostreptomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dihydrostreptomycin.Investigational
BendazacBendazac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type ADihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BromfenacBromfenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental
BumadizoneBumadizone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dihydrostreptomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Dihydrostreptomycin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinDihydrostreptomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
CisatracuriumDihydrostreptomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateDihydrostreptomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
Clodronic AcidDihydrostreptomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
ColistimethateDihydrostreptomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
CyclacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineDihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Dihydrostreptomycin.Experimental
DecamethoniumDihydrostreptomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Dihydrostreptomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dihydrostreptomycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dihydrostreptomycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Dihydrostreptomycin.Approved
Domoic AcidDihydrostreptomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideDihydrostreptomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
DuvelisibDuvelisib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dihydrostreptomycin.Approved, Investigational
EtanerceptEtanercept may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Etidronic acidDihydrostreptomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ExisulindExisulind may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dihydrostreptomycin.Approved, Vet Approved
GallamineDihydrostreptomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideDihydrostreptomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Dihydrostreptomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
IbandronateDihydrostreptomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Dihydrostreptomycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Dihydrostreptomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
MecamylamineDihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Dihydrostreptomycin.Experimental
MetocurineDihydrostreptomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideDihydrostreptomycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Withdrawn
MezlocillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumDihydrostreptomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftifineNaftifine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinDihydrostreptomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
NifenazoneNifenazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Dihydrostreptomycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Dihydrostreptomycin.Approved
OxacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaprozinOxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
PamidronateDihydrostreptomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumDihydrostreptomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PenamecillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Dihydrostreptomycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dihydrostreptomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumDihydrostreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Dihydrostreptomycin.Approved
PirfenidonePirfenidone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Dihydrostreptomycin.Experimental
PTC299PTC299 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
PyrantelDihydrostreptomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumDihydrostreptomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateDihydrostreptomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumDihydrostreptomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
SuccinylcholineDihydrostreptomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
SultamicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateDihydrostreptomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateDihydrostreptomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidDihydrostreptomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dihydrostreptomycin.Approved
TranilastTranilast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational
TubocurarineDihydrostreptomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Dihydrostreptomycin.Approved
VecuroniumDihydrostreptomycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidDihydrostreptomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
  1. CURCI G: [Dihydrostreptomycin]. Arch Tisiol Mal Appar Respir. 1951 Mar;6(3):Varia, 104-6. [PubMed:14830485]
  2. Midtvedt T: [Dihydrostreptomycin]. Tidsskr Nor Laegeforen. 1970 Apr 15;90(8):791. [PubMed:4194808]
  3. BARTZ QR, CONTROULIS J, et al.: Dihydrostreptomycin. J Am Chem Soc. 1946 Nov;68(11):2163-6. [PubMed:21002218]
  4. HARRISON WH: Dihydrostreptomycin deafness. Antibiot Annu. 1959-1960;7:549-51. [PubMed:14400056]
  5. SHAMBAUGH GE Jr, DERLACKI EL, HARRISON WH, HOUSE H, HOUSE W, HILDYARD V, SCHUKNECHT H, SHEA JJ: Dihydrostreptomycin deafness. J Am Med Assoc. 1959 Aug 1;170(14):1657-60. [PubMed:13672753]
  6. MAHADY SC, ARMSTRONG FL, MONROE J: Purified dihydrostreptomycin. Am Rev Tuberc. 1956 May;73(5):776-8. [PubMed:13313964]
  7. AGOPSOWICZ G, BEKIERKUNST A, HOCHBERGER B, JEDRZEJEWSKA A, KOSSOWSKI S: [Dihydrostreptomycin and dihydrostreptomycin-penicillin therapy of ozena]. Arch Immunol Ther Exp (Warsz). 1955;3:239-47. [PubMed:13395829]
  8. LEES JK, MARKLE DM: Dihydrostreptomycin and deafness. N Y State J Med. 1953 Dec 15;53(24):2997-9. [PubMed:13111505]
  9. Authors unspecified: [Dihydrostreptomycin in pulmonary tuberculosis]. Dia Med. 1951 Sep 24;23(64):2861; passim. [PubMed:14879647]
  10. SHANE SJ, LAURIE JH: Neurotoxicity of dihydrostreptomycin. Can Med Assoc J. 1950 Sep;63(3):277-9. [PubMed:15434767]
External Links
KEGG Drug
D07840
KEGG Compound
C01023
ChemSpider
388489
ChEBI
38291
ChEMBL
CHEMBL1950576
HET
71R
Wikipedia
Dihydrostreptomycin
ATC Codes
S01AA15 — Dihydrostreptomycin
PDB Entries
5lpa

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentBMI >30 kg/m2 / Metabolic Syndromes1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility16.0 mg/mLALOGPS
logP-3ALOGPS
logP-7.3ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)12.11ChemAxon
pKa (Strongest Basic)11.31ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count15ChemAxon
Polar Surface Area334.59 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity150.45 m3·mol-1ChemAxon
Polarizability56.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0001090000-e5c939b16a98cbc76e8f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0001090000-f492efdcf9b73dccff78
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0110090000-a21d136fb6ad87c99c54
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-1290020000-c272561234831b3053da
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03ka-1190000000-4c31681402bf294549fd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0090000000-094483dbe63a6b4a3a35
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0bvi-3940300000-adca1fa480c33dd8c023
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01w1-9570000000-da64f1603c2c8b791414
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fki-9340000000-915a5b4c2e2c08346763
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fgx-9010000000-0d0be639d3cdcb114f75
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-03di-0090010000-2014c0916e72e16177f4

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
O-glycosyl compounds / Cyclohexanols / Oxanes / Monosaccharides / Cyclitols and derivatives / Tetrahydrofurans / Tertiary alcohols / Guanidines / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds
show 8 more
Substituents
Amino cyclitol glycoside / Glycosyl compound / O-glycosyl compound / Cyclohexanol / Cyclitol or derivatives / Monosaccharide / Oxane / Cyclic alcohol / Tertiary alcohol / Tetrahydrofuran
show 20 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
streptomycins (CHEBI:38291)

Drug created on February 26, 2016 10:29 / Updated on February 03, 2018 15:07